Table 4.

Multivariable models evaluating factors associated with levels of AST and ALT among TF and CM study participants

	AST		ALT
Parameter of interest	Difference (%)	95% CI	Difference (%)	95% CI
Gender identity (TF vs CM)	−13	−19, −7	−19	−23, −16
Site (KPNC vs other)	2	−3, 6	8	5, 11
Age group (y) vs 18–25
26–35	2	−4, 8	8	4, 13
36–45	12	5, 19	12	7, 17
46–55	2	−4, 8	0	−4, 4
56+	1	−5, 7	−8	−12, −4
Race/ethnicity (vs NHW)
Non-Hispanic Black	7	0, 15	−6	−10, −2
Hispanic	4	−2, 9	9	5, 14
Asian/Pacific Islander	−4	−10, 3	3	−1, 8
Other/Unknown	−7	−16, 5	3	−3, 11
Body mass index (kg/m2) ≥25.0 vs <25.0	7	3, 13	31	27, 35
Alcohol use/abuse (yes vs no)	21	15, 27	12	7, 16
Time (10-d increments)
Pre-GAHT	−2	−7, 2	−10	−12, −6
Post-GAHT	−7	−16, 5	1	−6, 8
Pre-GAHT × gender identity	−10	−24, 6	−24	−32, −15
Post-GAHT × gender identity	6	−21, 45	7	−12, 30
Calculated adjusted average 10-d change (%)
TF pre-GAHT	−12	−25, 3	−31	−38, −23
TF post-GAHT	−13	−28, 7	−26	−34, −16
CM pre-GAHT	−2	−7, 2	−9	−12, −6
CM post-GAHT	−9	−16, 0	−9	−13, −4
Ratio-of-ratios for 10-d change among TF (post- vs pre-GAHT)	1.00	0.75, 1.32	1.08	0.90, 1.29
Ratio-of-ratios for post-GAHT 10-d change (TF vs CM)	0.96	0.77, 1.19	0.81	0.71, 0.93

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; CM = cisgender males; GAHT = gender affirming hormone therapy; KPNC = Kaiser Permanente Northern California; TF = transfeminine, NHW = non-Hispanic White.